Inhibition of AMP-activated protein kinase pathway sensitizes human leukemia K562 cells to nontoxic concentration of doxorubicin

Molecular and Cellular Biochemistry

Volumn 340, Issue 1-2, 2010, Pages 275-281

  Zhu, Qun ^a   Shen, Bo ^b   Zhang, Boshao ^c   Zhang, Wei ^d   Chin, Steve H ^e   Jin, Junfei ^f,g   Liao, Duan Fang ^f,g  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF SOUTH CHINA   (China)

^g HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

AMP activated protein kinase; Apoptosis; Cell death; Doxorubicin; Human leukemia K562 cell

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; COMPOUND C; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; (6-(4-(2-PIPERIDIN-1-YLETHOXY)PHENYL))-3-PYRIDIN-4-YLPYRAZOLO(1,5-A)PYRIMIDINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL KILLING; CELL STRAIN K 562; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENERGY BALANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; ERYTHROLEUKEMIA; GENETICS; K562 CELL LINE; METABOLISM; PATHOLOGY;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RNA INTERFERENCE;

EID: 77954426958     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0428-3     Document Type: Article

References (30)

1. RB Weiss 1992 The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 670 686 1:CAS:528:DyaK3sXhtl2jsbo%3D 1462166
2. G Minotti P Menna E Salvatorelli G Cairo L Gianni 2004 Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185 229 10.1124/pr.56.2.6 1:CAS:528: DC%2BD2cXltlKgtb0%3D 15169927 (Pubitemid 38720829)
3. M Czyz J Jakubowska M Sztiller-Sikorska 2008 STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562 Biochem Pharmacol 75 1761 1773 10.1016/j.bcp.2008.02.004 1:CAS:528: DC%2BD1cXkvFGht7g%3D 18346714
4. DA Gewirtz 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 57 727 741 10.1016/S0006-2952(98)00307-4 1:CAS:528:DyaK1MXhsFeksL8%3D 10075079 (Pubitemid 29094544)
5. DG Hardie D Carling M Carlson 1998 The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67 821 855 10.1146/annurev.biochem.67.1.821 1:CAS:528:DyaK1cXlsFOmtr4%3D 9759505 (Pubitemid 28411146)
6. HS Kim JT Hwang H Yun SG Chi SJ Lee I Kang KS Yoon WJ Choe SS Kim J Ha 2008 Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53 J Biol Chem 283 3731 3742 10.1074/jbc.M704432200 1:CAS:528:DC%2BD1cXhs1WgsL4%3D 18079115
7. M Tokarska-Schlattner M Zaugg R da Silva E Lucchinetti MC Schaub T Wallimann U Schlattner 2005 Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply Am J Physiol Heart Circ Physiol 289 H37 H47 10.1152/ajpheart.01057.2004 1:CAS:528:DC%2BD2MXmvVeqtr8%3D 15764680 (Pubitemid 40934080)
8. MM Shaw WK Gurr RJ McCrimmon DF Schorderet RS Sherwin 2007 5′AMP-activated protein kinase alpha deficiency enhances stress-induced apoptosis in BHK and PC12 cells J Cell Mol Med 11 286 298 10.1111/j.1582-4934. 2007.00023.x 1:CAS:528:DC%2BD2sXmsFykurg%3D 17488477 (Pubitemid 46693327)
9. CU Niesler KH Myburgh F Moore 2007 The changing AMPK expression profile in differentiating mouse skeletal muscle myoblast cells helps confer increasing resistance to apoptosis Exp Physiol 92 207 217 10.1113/expphysiol.2006.034736 1:CAS:528:DC%2BD2sXjsVeisbg%3D 16945942 (Pubitemid 46098899)
10. G Zhou R Myers Y Li Y Chen X Shen J Fenyk-Melody M Wu J Ventre T Doebber N Fujii N Musi MF Hirshman LJ Goodyear DE Moller 2001 Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 1167 1174 1:CAS:528:DC%2BD3MXns1ChsL4%3D 11602624
11. J Jin TD Mullen Q Hou J Bielawski A Bielawska X Zhang LM Obeid YA Hannun YT Hsu 2009 AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells J Lipid Res 50 2389 2397 10.1194/jlr.M900119-JLR200 1:CAS:528:DC%2BD1MXhsVyrsb%2FN 19528633
12. MJ Rossi K Sundararaj S Koybasi MS Phillips ZM Szulc A Bielawska TA Day LM Obeid YA Hannun B Ogretmen 2005 Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells Otolaryngol Head Neck Surg 132 55 62 10.1016/j.otohns.2004.08.015 15632910 (Pubitemid 40052672)
13. YH Zeidan BJ Pettus S Elojeimy T Taha LM Obeid T Kawamori JS Norris YA Hannun 2006 Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production J Biol Chem 281 24695 24703 10.1074/jbc.M604713200 1:CAS:528:DC%2BD28Xot1eqtLw%3D 16803890 (Pubitemid 44274243)
14. GG Steel MJ Peckham 1979 Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 5 85 91 1:STN:280:DyaE1M7jtVSrsQ%3D%3D 422420
15. BM Emerling B Viollet KV Tormos NS Chandel 2007 Compound C inhibits hypoxic activation of HIF-1 independent of AMPK FEBS Lett 581 5727 5731 10.1016/j.febslet.2007.11.038 1:CAS:528:DC%2BD2sXhtlykt7nI 18036344 (Pubitemid 350179784)
16. H Motoshima BJ Goldstein M Igata E Araki 2006 AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer J Physiol 574 63 71 10.1113/jphysiol.2006.108324 1:CAS:528:DC%2BD28XnsVyju7o%3D 16613876 (Pubitemid 43905797)
17. Z Luo AK Saha X Xiang NB Ruderman 2005 AMPK, the metabolic syndrome and cancer Trends Pharmacol Sci 26 69 76 10.1016/j.tips.2004.12.011 1:CAS:528:DC%2BD2MXoslahug%3D%3D 15681023 (Pubitemid 40170168)
18. K Kato T Ogura A Kishimoto Y Minegishi N Nakajima M Miyazaki H Esumi 2002 Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation Oncogene 21 6082 6090 10.1038/sj.onc.1205737 1:CAS:528:DC%2BD38XmsFGqsrc%3D 12203120
19. PP Kayampilly KM Menon 2009 Follicle-stimulating hormone inhibits adenosine 5′-monophosphate-activated protein kinase activation and promotes cell proliferation of primary granulosa cells in culture through an Akt-dependent pathway Endocrinology 150 929 935 10.1210/en.2008-1032 1:CAS:528:DC%2BD1MXhs1Sgtrw%3D 18927218
20. DG Hardie D Carling 1997 The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246 259 273 10.1111/j.1432-1033.1997.00259.x 1:CAS:528:DyaK2sXjvVGrsbs%3D 9208914
21. BE Kemp KI Mitchelhill D Stapleton BJ Michell ZP Chen LA Witters 1999 Dealing with energy demand: the AMP-activated protein kinase Trends Biochem Sci 24 22 25 10.1016/S0968-0004(98)01340-1 1:CAS:528:DyaK1MXks12qtLs%3D 10087918 (Pubitemid 29074459)
22. MR Munday 2002 Regulation of mammalian acetyl-CoA carboxylase Biochem Soc Trans 30 1059 1064 10.1042/BST0301059 1:CAS:528:DC%2BD38XovF2isbk%3D 12440972 (Pubitemid 36002406)
23. DG Hardie DA Pan 2002 Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase Biochem Soc Trans 30 1064 1070 10.1042/BST0301064 1:CAS:528:DC%2BD38XovF2isbY%3D 12440973 (Pubitemid 36002407)
24. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 332 344 10.1038/nrc2106 1:CAS:528:DC%2BD2sXksFSiu7w%3D 17457301 (Pubitemid 46652481)
25. BB Hasinoff D Patel KA O'Hara 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib Mol Pharmacol 74 1722 1728 10.1124/mol.108.050104 1:CAS:528:DC%2BD1cXhsVGls7rF 18815214
26. RD Olson PS Mushlin 1990 Doxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J 4 3076 3086 1:CAS:528:DyaK3MXhs12ktA%3D%3D 2210154
27. PM Sokolove 1994 Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity Int J Biochem 26 1341 1350 10.1016/0020-711X(94)90176-7 1:CAS:528:DyaK2MXjtVOjt74%3D 7890113
28. G Fang CN Kim CL Perkins N Ramadevi E Winton S Wittmann KN Bhalla 2000 CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood 96 2246 2253 1:CAS:528:DC%2BD3cXms1Chsbc%3D 10979973
29. J Jakubowska M Stasiak A Szulawska A Bednarek M Czyz 2007 Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562 Acta Biochim Pol 54 839 846 1:CAS:528:DC%2BD1cXkt1agtbw%3D 17957275
30. E Jabbour J Cortes H Kantarjian 2009 Treatment selection after imatinib resistance in chronic myeloid leukemia Target Oncol 4 3 10 10.1007/s11523-008- 0100-y 19343297